Vanguard Group
PLRX icon

Vanguard Group’s Pliant Therapeutics PLRX Stock Holding History

Vanguard Group’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.44M Buy
2,818,241
+42,303
+2% +$63.5K ﹤0.01% 3398
2025
Q3 		$4.11M Sell
2,775,938
-226,410
-8% -$345K ﹤0.01% 3335
2025
Q2 		$3.48M Sell
3,002,348
-332,227
-10% -$469K ﹤0.01% 3331
2025
Q1 		$4.5M Buy
3,334,575
+105,820
+3% +$642K ﹤0.01% 3220
2024
Q4 		$42.5M Sell
3,228,755
-297,759
-8% -$4.07M ﹤0.01% 2233
2024
Q3 		$39.5M Buy
3,526,514
+89,354
+3% +$1.12M ﹤0.01% 2281
2024
Q2 		$36.9M Sell
3,437,160
-41,195
-1% -$531K ﹤0.01% 2269
2024
Q1 		$51.8M Buy
3,478,355
+412,486
+13% +$6.8M ﹤0.01% 2150
2023
Q4 		$55.5M Buy
3,065,869
+120,557
+4% +$1.83M ﹤0.01% 2143
2023
Q3 		$51.1M Buy
2,945,312
+168,454
+6% +$2.92M ﹤0.01% 2128
2023
Q2 		$50.3M Buy
2,776,858
+404,136
+17% +$9.57M ﹤0.01% 2182
2023
Q1 		$63.1M Buy
2,372,722
+423,678
+22% +$12.1M ﹤0.01% 2061
2022
Q4 		$37.7M Buy
1,949,044
+349,720
+22% +$7.31M ﹤0.01% 2323
2022
Q3 		$33.4M Buy
1,599,324
+546,638
+52% +$10.5M ﹤0.01% 2382
2022
Q2 		$8.43M Sell
1,052,686
-180,013
-15% -$1.15M ﹤0.01% 3085
2022
Q1 		$8.64M Buy
1,232,699
+14,289
+1% +$146K ﹤0.01% 3233
2021
Q4 		$16.4M Sell
1,218,410
-200,189
-14% -$3.18M ﹤0.01% 2946
2021
Q3 		$23.9M Buy
1,418,599
+146,943
+12% +$3.12M ﹤0.01% 2758
2021
Q2 		$37M Buy
1,271,656
+168,971
+15% +$5.26M ﹤0.01% 2527
2021
Q1 		$43.4M Buy
1,102,685
+595,726
+118% +$19.3M ﹤0.01% 2395
2020
Q4 		$11.5M Buy
506,959
+65,966
+15% +$1.65M ﹤0.01% 2922
2020
Q3 		$9.99M Buy
440,993
+415,993
+1,664% +$10.4M ﹤0.01% 2791
2020
Q2 		$812K Buy
+25,000
New +$664K ﹤0.01% 3656

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Vanguard Group's PLRX Position: Q4 2025 in Review

Vanguard Group increased its Pliant Therapeutics (PLRX) stake by 1.5% in Q4 2025, buying an estimated $63.5K and bringing the position to 2,818,241 shares worth $3.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3398.

Vanguard Group first reported a position in PLRX in Q2 2020 and has held it in 23 quarters since. The position peaked at $63.1M in Q1 2023. 97 funds tracked by Wall St. Rank hold PLRX as of Q4 2025.

  • Vanguard Group held 2,818,241 shares of Pliant Therapeutics worth $3.44M as of Q4 2025.
  • Vanguard Group bought 42,303 Pliant Therapeutics shares in Q4 2025, an estimated $63.5K.
  • Pliant Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3398 holding.
  • Vanguard Group first reported a position in Pliant Therapeutics in Q2 2020 and has held it in 23 quarters since.
  • Vanguard Group's Pliant Therapeutics position peaked at $63.1M in Q1 2023.
  • 97 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.